Regulation and dysregulation of Epstein - Barr virus latency: Implications for the development of autoimmune diseases

Autoimmunity

Volumn 41, Issue 4, 2008, Pages 298-328

  Niller, Hans Helmut ^a   Wolf, Hans ^a   Minarovits, Janos ^b  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

Author keywords

Autoimmune diseases; B cell tolerance checkpoints; Epigenetic regulation; Epstein Barr virus; Immune surveillance defects; Latency control

Indexed keywords

COMPLEMENT COMPONENT C3D RECEPTOR; CYTOSINE; EBER PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; GLYCOPROTEIN GP350; GUANINE; IMMEDIATE EARLY PROTEIN BZLF1; INTERLEUKIN 1; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1; LATENT MEMBRANE PROTEIN 2; MESSENGER RNA; METHOTREXATE; MYC PROTEIN; PHOSPHATE; TUMOR NECROSIS FACTOR ALPHA; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BURKITT LYMPHOMA; CPG METHYLATION; DNA HISTONE INTERACTION; DNA METHYLATION; EPIGENETICS; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE SILENCING; GENETIC REGULATION; GENETIC SUSCEPTIBILITY; HODGKIN DISEASE; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IMMUNOSURVEILLANCE; LYMPHOBLASTOID CELL LINE; LYMPHOEPITHELIOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; MEMORY CELL; METHYLATION; MULTIPLE SCLEROSIS; NASOPHARYNX CARCINOMA; NONHUMAN; PATHOGENESIS; POSTOPERATIVE COMPLICATION; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; RNA VIRUS; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; VIRUS CELL INTERACTION; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS INFECTION; VIRUS LATENCY; VIRUS LOAD; VIRUS ONCOGENE; VIRUS REPLICATION; VIRUS TRANSMISSION; WALDEYER RING;

AUTOIMMUNE DISEASES; B-LYMPHOCYTES; EPIGENESIS, GENETIC; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; GENE EXPRESSION REGULATION, VIRAL; HERPESVIRUS 4, HUMAN; HUMANS; IMMUNOLOGIC MEMORY; RNA, VIRAL; VIRUS LATENCY; VIRUS REPLICATION;

EID: 42649142956     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930802024772     Document Type: Article

References (379)

1. Burkitt, D. (1958) A sarcoma involving the jaws in African children. Br J Surg, 45, pp. 218-223.
2. Burkitt, D. (1962) A children's cancer dependent upon climatic factors. Nature, 194, pp. 232-234.
3. Epstein, MA, Achong, BG and Barr, YM (1964) Virus particles in cultured lymphoblasts from Burkitt's lymphoma. Lancet, 1, pp. 702-703.
4. Pulvertaft, RJ (1964) Cytology of Burkitt's tumor (African lymphoma). Lancet, 1, pp. 238-240.
5. Henle, G., Henle, W. and Diehl, V. (1968) Relation of Burkitt's tumor-associated herpes-type virus to infectious mononucleosis. Proc Natl Acad Sci USA, 59, pp. 94-101.
6. Thompson, MP and Kurzrock, R. (2004) Epstein-Barr virus and cancer. Clin Cancer Res, 10, pp. 803-821.
7. Niller, HH, Wolf, H. and Minarovits, J. (2007) Epstein-Barr virus. Latency strategies of herpesviruses, pp. 154-191. Springer, New York
8. Shannon-Lowe, CD, Neuhierl, B., Baldwin, G., Rickinson, AB and Delecluse, HJ (2006) Resting B cells as a transfer vehicle for Epstein-Barr virus infection of epithelial cells. Proc Natl Acad Sci USA, 103, pp. 7065-7070.
9. Wolf, H., Haus, M. and Wilmes, E. (1984) Persistence of Epstein-Barr virus in the parotid gland. J Virol, 51, pp. 795-798.
10. Borza, CM and Hutt-Fletcher, LM (2002) Alternate replication in B cells and epithelial cells switches tropism of Epstein-Barr virus. Nat Med, 8, pp. 594-599.
11. Thorley-Lawson, DA and Gross, A. (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med, 350, pp. 1328-1337.
12. Souza, TA, Stollar, BD, Sullivan, JL, Luzuriaga, K. and Thorley-Lawson, DA (2005) Peripheral B cells latently infected with Epstein-Barr virus display molecular hallmarks of classical antigen-selected memory B cells. Proc Natl Acad Sci USA, 102, pp. 18093-18098.
13. Kurth, J., Spieker, T. and Wustrow, J. (2000) EBV-infected B cells in infectious mononucleosis: Viral strategies for spreading in the B cell compartment and establishing latency. Immunity, 13, pp. 485-495.
14. Kurth, J., Hansmann, ML, Rajewsky, K. and Kuppers, R. (2003) Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci USA, 100, pp. 4730-4735.
15. Ehlin-Henriksson, B., Gordon, J. and Klein, G. (2003) B-lymphocyte subpopulations are equally susceptible to Epstein-Barr virus infection, irrespective of immunoglobulin isotype expression. Immunology, 108, pp. 427-430.
16. Crawford, DH (2001) Biology and disease associations of Epstein-Barr virus. Philos Trans R Soc Lond B Biol Sci, 356, pp. 461-473.
17. Hochberg, D., Souza, T., Catalina, M., Sullivan, JL, Luzuriaga, K. and Thorley-Lawson, DA (2004) Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol, 78, pp. 5194-5204.
18. Tierney, RJ, Steven, N., Young, LS and Rickinson, AB (1994) Epstein-Barr virus latency in blood mononuclear cells: Analysis of viral gene transcription during primary infection and in the carrier state. J Virol, 68, pp. 7374-7385.
19. Tosato, G., Magrath, I., Koski, I., Dooley, N. and Blaese, M. (1979) Activation of suppressor T cells during Epstein-Barr-virus-induced infectious mononucleosis. N Engl J Med, 301, pp. 1133-1137.
20. Moss, DJ, Burrows, SR, Silins, SL, Misko, I. and Khanna, R. (2001) The immunology of Epstein-Barr virus infection. Philos Trans R Soc Lond B Biol Sci, 356, pp. 475-488.
21. Silins, SL, Sherritt, MA and Silleri, JM (2001) Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load. Blood, 98, pp. 3739-3744.
22. Niedobitek, G., Agathanggelou, A., Herbst, H., Whitehead, L., Wright, DH and Young, LS (1997) Epstein-Barr virus (EBV) infection in infectious mononucleosis: Virus latency, replication and phenotype of EBV-infected cells. J Pathol, 182, pp. 151-159.
23. Klein, E., Kis, LL and Klein, G. (2007) Epstein-Barr virus infection in humans: From harmless to life endangering virus-lymphocyte interactions. Oncogene, 26, pp. 1297-1305.
24. Niller, HH, Glaser, G., Knuchel, R. and Wolf, H. (1995) Nucleoprotein complexes and DNA 5′-ends at oriP of Epstein-Barr virus. J Biol Chem, 270, pp. 12864-12868.
25. Vogel, M., Wittmann, K. and Endl, E. (1998) Plasmid maintenance assay based on green fluorescent protein and FACS of mammalian cells. Biotechniques, 24, pp. 540-544.
26. Yates, JL, Camiolo, SM and Bashaw, JM (2000) The minimal replicator of Epstein-Barr virus oriP. J Virol, 74, pp. 4512-4522.
27. Deng, Z., Atanasiu, C. and Zhao, K. (2005) Inhibition of Epstein-Barr virus OriP function by tankyrase, a telomere-associated poly-ADP ribose polymerase that binds and modifies EBNA1. J Virol, 79, pp. 4640-4650.
28. Atanasiu, C., Deng, Z., Wiedmer, A., Norseen, J. and Lieberman, PM (2006) ORC binding to TRF2 stimulates OriP replication. EMBO Rep, 7, pp. 716-721.
29. Sixbey, JW, Lemon, SM and Pagano, JS (1986) A second site for Epstein-Barr virus shedding: The uterine cervix. Lancet, 2, pp. 1122-1124.
30. Walling, DM, Ray, AJ, Nichols, JE, Flaitz, CM and Nichols, CM (2007) Epstein-Barr virus infection of Langerhans cell precursors as a mechanism of oral epithelial entry, persistence, and reactivation. J Virol, 81, pp. 7249-7268.
31. Laichalk, LL and Thorley-Lawson, DA (2005) Terminal differentiation into plasma cells initiates the replicative cycle of Epstein-Barr virus in vivo. J Virol, 79, pp. 1296-1307.
32. Crawford, DH and Ando, I. (1986) EB virus induction is associated with B-cell maturation. Immunology, 59, pp. 405-409.
33. Seibl, R., Motz, M. and Wolf, H. (1986) Strain-specific transcription and translation of the BamHI Z area of Epstein-Barr virus. J Virol, 60, pp. 902-909.
34. Grogan, E., Jenson, H., Countryman, J., Heston, L., Gradoville, L. and Miller, G. (1987) Transfection of a rearranged viral DNA fragment, WZhet, stably converts latent Epstein-Barr viral infection to productive infection in lymphoid cells. Proc Natl Acad Sci USA, 84, pp. 1332-1336.
35. Countryman, J., Jenson, H., Seibl, R., Wolf, H. and Miller, G. (1987) Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency. J Virol, 61, pp. 3672-3679.
36. Hardwick, JM, Lieberman, PM and Hayward, SD (1988) A new Epstein-Barr virus transactivator, R, induces expression of a cytoplasmic early antigen. J Virol, 62, pp. 2274-2284.
37. Marschall, M., Leser, U., Seibl, R. and Wolf, H. (1989) Identification of proteins encoded by Epstein-Barr virus trans-activator genes. J Virol, 63, pp. 938-942.
38. Sinclair, AJ, Brimmell, M., Shanahan, F. and Farrell, PJ (1991) Pathways of activation of the Epstein-Barr virus productive cycle. J Virol, 65, pp. 2237-2244.
39. Chan, AT, Tao, Q. and Robertson, KD (2004) Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors. J Clin Oncol, 22, pp. 1373-1381.
40. Amon, W. and Farrell, PJ (2005) Reactivation of Epstein-Barr virus from latency. Rev Med Virol, 15, pp. 149-156.
41. Feng, WH, Kraus, RJ, Dickerson, SJ, Lim, HJ, Jones, RJ, Yu, X., Mertz, JE and Kenney, SC (2007) ZEB1 and c-Jun levels contribute to the establishment of highly lytic Epstein-Barr virus injection in gastric AGS cells. J Virol, 81, pp. 10113-10122.
42. Feng, WH and Kenney, SC (2006) Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res, 66, pp. 8762-8769.
43. Wang, F., Gregory, C. and Sample, C. (1990) Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J Virol, 64, pp. 2309-2318.
44. Cheung, ST, Huang, DP and Hui, AB (1999) Nasopharyngeal carcinoma cell line (C666-1) consistently harbouring Epstein-Barr virus. Int J Cancer, 83, pp. 121-126.
45. Salamon, D., Takacs, M. and Ujvari, D. (2001) Protein-DNA binding and CpG methylation at nucleotide resolution of latency-associated promoters Qp, Cp, and LMP1p of Epstein-Barr virus. J Virol, 75, pp. 2584-2596.
46. Niller, HH, Salamon, D., Banati, F., Schwarzmann, F., Wolf, H. and Minarovits, J. (2004) The LCR of EBV makes Burkitt's lymphoma endemic. Trends Microbiol, 12, pp. 495-499.
47. Young, LS, Dawson, CW and Clark, D. (1988) Epstein-Barr virus gene expression in nasopharyngeal carcinoma. J Gen Virol, 65, pp. 1051-1065.
48. Niedobitek, G., Young, LS, Sam, CK, Brooks, L., Prasad, U. and Rickinson, AB (1992) Expression of Epstein-Barr virus genes and of lymphocyte activation molecules in undifferentiated nasopharyngeal carcinomas. Am J Pathol, 140, pp. 879-887.
49. Rowe, DT (1999) Epstein-Barr virus immortalization and latency. Front Biosci, 4, pp. D346-D371.
50. Rowe, M., Rowe, DT and Gregory, CD (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J, 6, pp. 2743-2751.
51. Gregory, CD, Rowe, M. and Rickinson, AB (1990) Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line. J Gen Virol, 71, pp. 1481-1495.
52. Pajic, A., Polack, A. and Staege, MS (2001) Elevated expression of c-myc in lymphoblastoid cells does not support an Epstein-Barr virus latency III-to-I switch. J Gen Virol, 82, pp. 3051-3055.
53. Pokrovskaja, K., Ehlin-Henriksson, B. and Kiss, C. (2002) CD40 ligation downregulates EBNA-2 and LMP-1 expression in EBV-transformed lymphoblastoid cell lines. Int J Cancer, 99, pp. 705-712.
54. Smith, PR, Gao, Y., Karran, L., Jones, MD, Snudden, D. and Griffin, BE (1993) Complex nature of the major viral polyadenylated transcripts in Epstein-Barr virus-associated tumors. J Virol, 67, pp. 3217-3225.
55. Sadler, RH and Raab-Traub, N. (1995) The Epstein-Barr virus 3.5-kilobase latent membrane protein 1 mRNA initiates from a TATA-less promoter within the first terminal repeat. J Virol, 69, pp. 4577-4581.
56. Sadler, RH and Raab-Traub, N. (1995) Structural analyses of the Epstein-Barr virus BamHI A transcripts. J Virol, 69, pp. 1132-1141.
57. Chen, H., Huang, J., Wu, FY, Liao, G., Hutt-Fletcher, L. and Hayward, SD (2005) Regulation of expression of the Epstein-Barr virus BamHI-A rightward transcripts. J Virol, 79, pp. 1724-1733.
58. Arrand, JR and Rymo, L. (1982) Characterization of the major Epstein-Barr virus-specific RNA in Burkitt lymphoma-derived cells. J Virol, 41, pp. 376-389.
59. Felton-Edkins, ZA, Kondrashov, A. and Karali, D. (2006) Epstein-Barr virus induces cellular transcription factors to allow active expression of EBER genes by RNA polymerase III. J Biol Chem, 281, pp. 33871-33880.
60. Lerner, MR, Andrews, NC, Miller, G. and Steitz, JA (1981) Two small RNAs encoded by Epstein-Barr virus and complexed with protein are precipitated by antibodies from patients with systemic lupus erythematosus. Proc Natl Acad Sci USA, 78, pp. 805-809.
61. Toczyski, DP, Matera, AG, Ward, DC and Steitz, JA (1994) The Epstein-Barr virus (EBV) small RNA EBER1 binds and relocalizes ribosomal protein L22 in EBV-infected human B lymphocytes. Proc Natl Acad Sci USA, 91, pp. 3463-3467.
62. Fok, V., Friend, K. and Steitz, JA (2006) Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling. J Cell Biol, 173, pp. 319-325.
63. Clarke, PA, Schwemmle, M., Schickinger, J., Hilse, K. and Clemens, MJ (1991) Binding of Epstein-Barr virus small RNA EBER-1 to the double-stranded RNA-activated protein kinase DAI. Nucleic Acids Res, 19, pp. 243-248.
64. Elia, A., Vyas, J., Laing, KG and Clemens, MJ (2004) Ribosomal protein L22 inhibits regulation of cellular activities by the Epstein-Barr virus small RNA EBER-1. Eur J Biochem, 271, pp. 1895-1905.
65. Komano, J., Maruo, S., Kurozumi, K., Oda, T. and Takada, K. (1999) Oncogenic role of Epstein-Barr virus-encoded RNAs in Burkitt's lymphoma cell line Akata. J Virol, 73, pp. 9827-9831.
66. Ruf, IK, Rhyne, PW, Yang, C., Cleveland, JL and Sample, JT (2000) Epstein-Barr virus small RNAs potentiate tumorigenicity of Burkitt lymphoma cells independently of an effect on apoptosis. J Virol, 74, pp. 10223-10228.
67. Ruf, IK, Lackey, KA, Warudkar, S. and Sample, JT (2005) Protection from interferon-induced apoptosis by Epstein-Barr virus small RNAs is not mediated by inhibition of PKR. J Virol, 79, pp. 14562-14569.
68. Clemens, MJ (2006) Epstein-Barr virus: Inhibition of apoptosis as a mechanism of cell transformation. Int J Biochem Cell Biol, 38, pp. 164-169.
69. Sugden, B. and Warren, N. (1989) A promoter of Epstein-Barr virus that can function during latent infection can be transactivated by EBNA-1, a viral protein required for viral DNA replication during latent infection. J Virol, 63, pp. 2644-2649.
70. Jankelevich, S., Kolman, JL, Bodnar, JW and Miller, G. (1992) A nuclear matrix attachment region organizes the Epstein-Barr viral plasmid in Raji cells into a single DNA domain. EMBO J, 11, pp. 1165-1176.
71. Middleton, T. and Sugden, B. (1994) Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. J Virol, 68, pp. 4067-4071.
72. White, RE, Wade-Martins, R. and James, MR (2001) Sequences adjacent to oriP improve the persistence of Epstein-Barr virus-based episomes in B cells. J Virol, 75, pp. 11249-11252.
73. Wensing, B., Stuhler, A., Jenkins, P., Hollyoake, M., Karstegl, CE and Farrell, PJ (2001) Variant chromatin structure of the oriP region of Epstein-Barr virus and regulation of EBER1 expression by upstream sequences and oriP. J Virol, 75, pp. 6235-6241.
74. Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A. and Masucci, MG (1997) Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA, 94, pp. 12616-12621.
75. Rabson, M., Gradoville, L., Heston, L. and Miller, G. (1982) Non-immortalizing P3J-HR-1 Epstein-Barr virus: A deletion mutant of its transforming parent, Jijoye. J Virol, 44, pp. 834-844.
76. Hammerschmidt, W. and Sugden, B. (1989) Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes. Nature, 340, pp. 393-397.
77. Ling, PD, Rawlins, DR and Hayward, SD (1993) The Epstein-Barr virus immortalizing protein EBNA-2 is targeted to DNA by a cellular enhancer-binding protein. Proc Natl Acad Sci USA, 90, pp. 9237-9241.
78. Cordier, M., Calender, A. and Billaud, M. (1990) Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol, 64, pp. 1002-1013.
79. Wang, F., Tsang, SF, Kurilla, MG, Cohen, JI and Kieff, E. (1990) Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1. J Virol, 64, pp. 3407-3416.
80. Mannick, JB, Cohen, JI, Birkenbach, M., Marchini, A. and Kieff, E. (1991) The Epstein-Barr virus nuclear protein encoded by the leader of the EBNA RNAs is important in B-lymphocyte transformation. J Virol, 65, pp. 6826-6837.
81. Harada, S. and Kieff, E. (1997) Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation. J Virol, 71, pp. 6611-6618.
82. Nitsche, F., Bell, A. and Rickinson, A. (1997) Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: A role for the W1W2 repeat domain. J Virol, 71, pp. 6619-6628.
83. Sinclair, AJ, Palmero, I., Peters, G. and Farrell, PJ (1994) EBNA-2 and BNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J, 13, pp. 3321-3328.
84. Peng, CW, Xue, Y., Zhao, B., Johannsen, E., Kieff, E. and Harada, S. (2004) Direct interactions between Epstein-Barr virus leader protein LP and the EBNA2 acidic domain underlie coordinate transcriptional regulation. Proc Natl Acad Sci USA, 101, pp. 1033-1038.
85. Szekely, L., Pokrovskaja, K., Jiang, WQ, de The, H., Ringertz, N. and Klein, G. (1996) The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies. J Virol, 70, pp. 2562-2568.
86. Tomkinson, B., Robertson, E. and Kieff, E. (1993) Epstein-Barr virus nuclear proteins EBNA-3A and EBNA-3C are essential for B-lymphocyte growth transformation. J Virol, 67, pp. 2014-2025.
87. Tomkinson, B. and Kieff, E. (1992) Use of second-site homologous recombination to demonstrate that Epstein-Barr virus nuclear protein 3B is not important for lymphocyte infection or growth transformation in vitro. J Virol, 66, pp. 2893-2903.
88. Waltzer, L., Perricaudet, M., Sergeant, A. and Manet, E. (1996) Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA. J Virol, 70, pp. 5909-5915.
89. Robertson, ES, Lin, J. and Kieff, E. (1996) The amino-terminal domains of Epstein-Barr virus nuclear proteins 3A, 3B, and 3C interact with RBPJ(kappa). J Virol, 70, pp. 3068-3074.
90. Chen, A., Zhao, B., Kieff, E., Aster, JC and Wang, F. (2006) EBNA-3B- and EBNA-3C-regulated cellular genes in Epstein-Barr virus-immortalized lymphoblastoid cell lines. J Virol, 80, pp. 10139-10150.
91. Smith, P. (2001) Epstein-Barr virus complementary strand transcripts (CSTs/BARTs) and cancer. Semin Cancer Biol, 11, pp. 469-476.
92. de Jesus, O., Smith, PR and Spender, LC (2003) Updated Epstein-Barr virus (EBV) DNA sequence and analysis of a promoter for the BART (CST, BARF0) RNAs of EBV. J Gen Virol, 84, pp. 1443-1450.
93. Laux, G., Dugrillon, F., Eckert, C., Adam, B., Zimber-Strobl, U. and Bornkamm, GW (1994) Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes. J Virol, 68, pp. 6947-6958.
94. Fennewald, S., van Santen, V. and Kieff, E. (1984) Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J Virol, 51, pp. 411-419.
95. Iwatsuki, K., Yamamoto, T. and Tsuji, K. (2004) A spectrum of clinical manifestations caused by host immune responses against Epstein-Barr virus infections. Acta Med Okayama, 58, pp. 169-180.
96. Andersson, J. (2000) An Overview of Epstein-Barr virus: From discovery to future directions for treatment and prevention. Herpes, 7, pp. 76-82.
97. Niedobitek, G., Meru, N. and Delecluse, HJ (2001) Epstein-Barr virus infection and human malignancies. Int J Exp Pathol, 82, pp. 149-170.
98. Knecht, H., Berger, C., Rothenberger, S., Odermatt, BF and Brousset, P. (2001) The role of Epstein-Barr virus in neoplastic transformation. Oncology, 60, pp. 289-302.
99. Gottschalk, S., Rooney, CM and Heslop, HE (2005) Post-transplant lymphoproliferative disorders. Annu Rev Med, 56, pp. 29-44.
100. Brink, AA, Dukers, DF and Brule, AJ van den (1997) Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol, 50, pp. 911-918.
101. Rickinson, AB, Finerty, S. and Epstein, MA (1977) Comparative studies on adult donor lymphocytes infected by EB virus in vivo or in vitro: Origin of transformed cells arising in co-cultures with foetal lymphocytes. Int J Cancer, 19, pp. 775-782.
102. Piovan, E., Bonaldi, L. and Indraccolo, S. (2003) Tumor outgrowth in peripheral blood mononuclear cell-injected SCID mice is not associated with early Epstein-Barr virus reactivation. Leukemia, 17, pp. 1643-1649.
103. Hong, GK, Gulley, ML, Feng, WH, Delecluse, HJ, Holley-Guthrie, E. and Kenney, SC (2005) Epstein-Barr virus lytic infection contributes to lymphoproliferative disease in a SCID mouse model. J Virol, 79, pp. 13993-14003.
104. Burns, DM and Crawford, DH (2004) Epstein-Barr virus-specific cytotoxic T-lymphocytes for adoptive immunotherapy of post-transplant lymphoproliferative disease. Blood Rev, 18, pp. 193-209.
105. Gregory, CD, Murray, RJ, Edwards, CF and Rickinson, AB (1988) Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance. J Exp Med, 167, pp. 1811-1824.
106. Bosch, CA van den (2004) Is endemic Burkitt's lymphoma an alliance between three infections and a tumour promoter?. Lancet Oncol, 5, pp. 738-746.
107. Magrath, I. (1990) The pathogenesis of Burkitt's lymphoma. Adv Cancer Res, 55, pp. 133-270.
108. Hecht, JL and Aster, JC (2000) Molecular biology of Burkitt's lymphoma. J Clin Oncol, 18, pp. 3707-3721.
109. Cheng, SW, Davies, KP, Yung, E., Beltran, RJ, Yu, J. and Kalpana, GV (1999) c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet, 22, pp. 102-105.
110. Waitz, W. and Loidl, P. (1991) Cell cycle dependent association of c-myc protein with the nuclear matrix. Oncogene, 6, pp. 29-35.
111. Goossens, T., Klein, U. and Kuppers, R. (1998) Frequent occurrence of deletions and duplications during somatic hypermutation: Implications for oncogene translocations and heavy chain disease. Proc Natl Acad Sci USA, 95, pp. 2463-2468.
112. Rooney, CM, Rowe, M., Wallace, LE and Rickinson, AB (1985) Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance. Nature, 317, pp. 629-631.
113. Lenoir, GM and Bornkamm, G. (1987) Burkitt's lymphoma, a human cancer model for the study of the multistep dvelopment of cancer: Proposal for a new scenario. Advances in viral oncology, pp. 173-206. Raven Press, New York
114. Klein, G. (1987) In defense of the "old" Burkitt lymphoma scenario. Advances in viral oncology, pp. 207-211. Raven Press, New York
115. Rossi, G. and Bonetti, F. (2004) EBV and Burkitt's lymphoma. N Engl J Med, 350, p. 2621.
116. Magrath, I., Jain, V. and Bhatia, K. (1992) Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol, 3, pp. 285-295.
117. Kelly, G., Bell, A. and Rickinson, A. (2002) Epstein-Barr virus-associated Burkitt lymphomagenesis selects for downregulation of the nuclear antigen EBNA2. Nat Med, 8, pp. 1098-1104.
118. Niller, HH, Salamon, D. and Ilg, K. (2003) The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis. Med Sci Monit, 9, pp. HY1-HY9.
119. Niller, HH, Salamon, D. and Ilg, K. (2004) EBV-associated neoplasms: Alternative pathogenetic pathways. Med Hypotheses, 62, pp. 387-391.
120. Pelengaris, S., Khan, M. and Evan, GI (2002) Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell, 109, pp. 321-334.
121. Marshall, NA, Christie, LE and Munro, LR (2004) Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood, 103, pp. 1755-1762.
122. Kuppers, R., Schwering, I., Brauninger, A., Rajewsky, K. and Hansmann, ML (2002) Biology of Hodgkin's lymphoma. Ann Oncol, 13, pp. 11-18.
123. Hjalgrim, H., Askling, J. and Rostgaard, K. (2003) Characteristics of Hodgkin's lymphoma after infectious mononucleosis. N Engl J Med, 349, pp. 1324-1332.
124. Weiss, LM, Movahed, LA, Warnke, RA and Sklar, J. (1989) Detection of Epstein-Barr viral genomes in Reed-Sternberg cells of Hodgkin's disease. N Engl J Med, 320, pp. 502-506.
125. Bargou, RC, Emmerich, F. and Krappmann, D. (1997) Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest, 100, pp. 2961-2969.
126. Duraiswamy, J., Sherritt, M. and Thomson, S. (2003) Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma. Blood, 101, pp. 3150-3156.
127. Bollard, CM, Aguilar, L. and Straathof, KC (2004) Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med, 200, pp. 1623-1633.
128. Lo, KW, To, KF and Huang, DP (2004) Focus on nasopharyngeal carcinoma. Cancer Cell, 5, pp. 423-428.
129. Wolf, H., Hausen, H zur and Becker, V. (1973) EB viral genomes in epithelial nasopharyngeal carcinoma cells. Nat New Biol, 244, pp. 245-247.
130. Desgranges, C., Wolf, H. and de The, G. (1975) Nasopharyngeal carcinoma X. Presence of Epstein-Barr genomes in separated epithelial cells of tumours in patients from Singapore, Tunisia and Kenya. Int J Cancer, 16, pp. 7-15.
131. Nicholls, JM, Agathanggelou, A., Fung, K., Zeng, X. and Niedobitek, G. (1997) The association of squamous cell carcinomas of the nasopharynx with Epstein-Barr virus shows geographical variation reminiscent of Burkitt's lymphoma. J Pathol, 183, pp. 164-168.
132. Hildesheim, A., Apple, RJ and Chen, CJ (2002) Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst, 94, pp. 1780-1789.
133. Zeng, Y. (1985) Seroepidemiological studies on nasopharyngeal carcinoma in China. Adv Cancer Res, 44, pp. 121-138.
134. Ito, Y., Ohigashi, H., Koshimizu, K. and Yi, Z. (1983) Epstein-Barr virus-activating principle in the ether extracts of soils collected from under plants which contain active diterpene esters. Cancer Lett, 19, pp. 113-117.
135. Ho, JH, Huang, DP and Fong, YY (1978) Salted fish and nasopharyngeal carcinoma in southern Chinese. Lancet, 2, p. 626.
136. Henle, G. and Henle, W. (1976) Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer, 17, pp. 1-7.
137. Straathof, KC, Bollard, CM and Popat, U. (2005) Treatment of nasopharyngeal carcinoma with Epstein-Barr virus-specific T lymphocytes. Blood, 105, pp. 1898-1904.
138. Osato, T. and Imai, S. (1996) Epstein-Barr virus and gastric carcinoma. Semin Cancer Biol, 7, pp. 175-182.
139. Hausen, A zur, Brink, AA, Craanen, ME, Middeldorp, JM, Meijer, CJ and Brule, AJ van den (2000) Unique transcription pattern of Epstein-Barr virus (EBV) in EBV-carrying gastric adenocarcinomas: Expression of the transforming BARF1 gene. Cancer Res, 60, pp. 2745-2748.
140. Seto, E., Yang, L. and Middeldorp, J. (2005) Epstein-Barr virus (EBV)-encoded BARF1 gene is expressed in nasopharyngeal carcinoma and EBV-associated gastric carcinoma tissues in the absence of lytic gene expression. J Med Virol, 76, pp. 82-88.
141. McClain, KL, Leach, CT and Jenson, HB (1995) Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med, 332, pp. 12-18.
142. Lee, ES, Locker, J. and Nalesnik, M. (1995) The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med, 332, pp. 19-25.
143. Jones, JF, Shurin, S. and Abramowsky, C. (1988) T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections. N Engl J Med, 318, pp. 733-741.
144. Pallesen, G., Hamilton-Dutoit, SJ and Zhou, X. (1993) The association of Epstein-Barr virus (EBV) with T cell lymphoproliferations and Hodgkin's disease: Two new developments in the EBV field. Adv Cancer Res, 62, pp. 179-239.
145. Harabuchi, Y., Yamanaka, N. and Kataura, A. (1990) Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma. Lancet, 335, pp. 128-130.
146. Minarovits, J., Hu, LF and Imai, S. (1994) Clonality, expression and methylation patterns of the Epstein-Barr virus genomes in lethal midline granulomas classified as peripheral angiocentric T cell lymphomas. J Gen Virol, 75, pp. 77-84.
147. Labrecque, LG, Barnes, DM, Fentiman, IS and Griffin, BE (1995) Epstein-Barr virus in epithelial cell tumors: A breast cancer study. Cancer Res, 55, pp. 39-45.
148. Bonnet, M., Guinebretiere, JM and Kremmer, E. (1999) Detection of Epstein-Barr virus in invasive breast cancers. J Natl Cancer Inst, 91, pp. 1376-1381.
149. Fina, F., Romain, S. and Ouafik, L. (2001) Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas. Br J Cancer, 84, pp. 783-790.
150. Arbach, H., Viglasky, V. and Lefeu, F. (2006) Epstein-Barr virus (EBV) genome and expression in breast cancer tissue: Effect of EBV infection of breast cancer cells on resistance to paclitaxel (Taxol). J Virol, 80, pp. 845-853.
151. Chu, PG, Chang, KL, Chen, YY, Chen, WG and Weiss, LM (2001) No significant association of Epstein-Barr virus infection with invasive breast carcinoma. Am J Pathol, 159, pp. 571-578.
152. Herrmann, K. and Niedobitek, G. (2002) Lack of evidence for an association of Epstein-Barr virus infection with breast carcinoma. Breast Cancer Res, 5, pp. R13-R17.
153. Deshpande, CG, Badve, S., Kidwai, N. and Longnecker, R. (2002) Lack of expression of the Epstein-Barr Virus (EBV) gene products, EBERs, EBNA1, LMP1, and LMP2A, in breast cancer cells. Lab Invest, 82, pp. 1193-1199.
154. Murray, PG, Lissauer, D. and Junying, J. (2003) Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. Cancer Res, 63, pp. 2338-2343.
155. Hamilton-Dutoit, SJ, Raphael, M. and Audouin, J. (1993) In situ demonstration of Epstein-Barr virus small RNAs (EBER 1) in acquired immunodeficiency syndrome-related lymphomas: Correlation with tumor morphology and primary site. Blood, 82, pp. 619-624.
156. Timms, JM, Bell, A. and Flavell, JR (2003) Target cells of Epstein-Barr-virus (EBV)-positive post-transplant lymphoproliferative disease: Similarities to EBV-positive Hodgkin's lymphoma. Lancet, 361, pp. 217-223.
157. Yin, CC, Medeiros, LJ, Abruzzo, LV, Jones, D., Farhood, AI and Thomazy, VA (2005) EBV-associated B- and T-cell posttransplant lymphoproliferative disorders following primary EBV infection in a kidney transplant recipient. Am J Clin Pathol, 123, pp. 222-228.
158. Meerbach, A., Gruhn, B., Egerer, R., Reischl, U., Zintl, F. and Wutzler, P. (2001) Semiquantitative PCR analysis of Epstein-Barr virus DNA in clinical samples of patients with EBV-associated diseases. J Med Virol, 65, pp. 348-357.
159. Wagner, HJ, Wessel, M. and Jabs, W. (2001) Patients at risk for development of posttransplant lymphoproliferative disorder: Plasma versus peripheral blood mononuclear cells as material for quantification of Epstein-Barr viral load by using real-time quantitative polymerase chain reaction. Transplantation, 72, pp. 1012-1019.
160. Swinnen, LJ (2000) Transplantation-related lymphoproliferative disorder: A model for human immunodeficiency virus-related lymphomas. Semin Oncol, 27, pp. 402-408.
161. Williams, H. and Crawford, DH (2006) Epstein-Barr virus: The impact of scientific advances on clinical practice. Blood, 107, pp. 862-869.
162. Milone, MC, Tsai, DE and Hodinka, RL (2005) Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell-directed therapy. Blood, 105, pp. 994-996.
163. Van Baarle, D., Wolthers, KC and Hovenkamp, E. (2002) Absolute level of Epstein-Barr virus DNA in human immunodeficiency virus type 1 infection is not predictive of AIDS-related non-Hodgkin lymphoma. J Infect Dis, 186, pp. 405-409.
164. Fellner, MD, Durand, K. and Correa, RM (2007) Circulating Epstein-Barr virus (EBV) in HIV-infected patients and its relation with primary brain lymphoma. Int J Infect Dis, 11, pp. 172-178.
165. Piriou, ER, van Dort, K., Nanlohy, NM, Miedema, F., Van Oers, MH and Van Baarle, D. (2004) Altered EBV viral load setpoint after HIV seroconversion is in accordance with lack of predictive value of EBV load for the occurrence of AIDS-related non-Hodgkin lymphoma. J Immunol, 172, pp. 6931-6937.
166. Ling, PD, Vilchez, RA and Keitel, WA (2003) Epstein-Barr virus DNA loads in adult human immunodeficiency virus type 1-infected patients receiving highly active antiretroviral therapy. Clin Infect Dis, 37, pp. 1244-1249.
167. Righetti, E., Ballon, G. and Ometto, L. (2002) Dynamics of Epstein-Barr virus in HIV-1-infected subjects on highly active antiretroviral therapy. AIDS, 16, pp. 63-73.
168. Stevens, SJ, Blank, BS, Smits, PH, Meenhorst, PL and Middeldorp, JM (2002) High Epstein-Barr virus (EBV) DNA loads in HIV-infected patients: Correlation with antiretroviral therapy and quantitative EBV serology. AIDS, 16, pp. 993-1001.
169. Van Baarle, D., Hovenkamp, E. and Callan, MF (2001) Dysfunctional Epstein-Barr virus (EBV)-specific CD8(+) T lymphocytes and increased EBV load in HIV-1 infected individuals progressing to AIDS-related non-Hodgkin lymphoma. Blood, 98, pp. 146-155.
170. Bossolasco, S., Falk, KI and Ponzoni, M. (2006) Ganciclovir is associated with low or undetectable Epstein-Barr virus DNA load in cerebrospinal fluid of patients with HIV-related primary central nervous system lymphoma. Clin Infect Dis, 42, pp. e21-e25.
171. Fan, W., Bubman, D., Chadburn, A., Harrington Jr., WJ, Cesarman, E. and Knowles, DM (2005) Distinct subsets of primary effusion lymphoma can be identified based on their cellular gene expression profile and viral association. J Virol, 79, pp. 1244-1251.
172. Facer, CA and Playfair, JH (1989) Malaria, Epstein-Barr virus, and the genesis of lymphomas. Adv Cancer Res, 53, pp. 33-72.
173. Lam, KM, Syed, N., Whittle, H. and Crawford, DH (1991) Circulating Epstein-Barr virus-carrying B cells in acute malaria. Lancet, 337, pp. 876-878.
174. Yone, CL, Kube, D., Kremsner, PG and Luty, AJ (2006) Persistent Epstein-Barr viral reactivation in young African children with a history of severe Plasmodium falciparum malaria. Trans R Soc Trop Med Hyg, 100, pp. 669-676.
175. Rasti, N., Falk, KI and Donati, D. (2005) Circulating Epstein-Barr virus in children living in malaria-endemic areas. Scand J Immunol, 61, pp. 461-465.
176. Moormann, AM, Chelimo, K. and Sumba, OP (2005) Exposure to holoendemic malaria results in elevated Epstein-Barr virus loads in children. J Infect Dis, 191, pp. 1233-1238.
177. Donati, D., Espmark, E. and Kironde, F. (2006) Clearance of circulating Epstein-Barr virus DNA in children with acute malaria after antimalaria treatment. J Infect Dis, 193, pp. 971-977.
178. Donati, D., Zhang, LP and Chene, A. (2004) Identification of a polyclonal B-cell activator in Plasmodium falciparum. Infect Immun, 72, pp. 5412-5418.
179. Donati, D., Mok, B. and Chene, A. (2006) Increased B cell survival and preferential activation of the memory compartment by a malaria polyclonal B cell activator. J Immunol, 177, pp. 3035-3044.
180. Chene, A., Donati, D. and Guerreiro-Cacais, AO (2007) Molecular link between malaria and Epstein-Barr virus reactivation. PLoS Pathog, 3, p. e80.
181. Evans, AS, Rothfield, NF and Niederman, JC (1971) Raised antibody titres to E.B. virus in systemic lupus erythematosus. Lancet, 1, pp. 167-168.
182. Pender, MP (2003) Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol, 24, pp. 584-588.
183. Wong, M. and Tsao, BP (2006) Current topics in human SLE genetics. Springer Semin Immunopathol, 28, pp. 97-107.
184. Ascherio, A. and Munger, KL (2007) Environmental risk factors for multiple sclerosis. Part I: The role of infection. Ann Neurol, 61, pp. 288-299.
185. Ascherio, A. and Munger, KL (2007) Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann Neurol, 61, pp. 504-513.
186. Poser, CM (1994) Notes on the pathogenesis of multiple sclerosis. Clin Neurosci, 2, pp. 258-265.
187. Reiber, H., Ungefehr, S. and Jacobi, C. (1998) The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler, 4, pp. 111-117.
188. Grufferman, S. and Delzell, E. (1984) Epidemiology of Hodgkin's disease. Epidemiol Rev, 6, pp. 76-106.
189. Newell, GR (1970) Etiology of multiple sclerosis and Hodgkin's disease. Am J Epidemiol, 91, pp. 119-122.
190. Olerup, O. and Hillert, J. (1991) HLA class II-associated genetic susceptibility in multiple sclerosis: A critical evaluation. Tissue Antigens, 38, pp. 1-15.
191. Kurtzke, JF (1993) Epidemiologic evidence for multiple sclerosis as an infection. Clin Microbiol Rev, 6, pp. 382-427.
192. Kurtzke, JF and Heltberg, A. (2001) Multiple sclerosis in the Faroe Islands: An epitome. J Clin Epidemiol, 54, pp. 1-22.
193. Perron, H., Garson, JA and Bedin, F. (1997) Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci USA, 94, pp. 7583-7588.
194. Batinac, T., Petranovic, D., Zamolo, G., Petranovic, D. and Ruzic, A. (2007) Lyme borreliosis and multiple sclerosis are associated with primary effusion lymphoma. Med Hypotheses, 69, pp. 117-119.
195. Gilden, DH (2005) Infectious causes of multiple sclerosis. Lancet Neurol, 4, pp. 195-202.
196. Christensen, T. (2005) Association of human endogenous retroviruses with multiple sclerosis and possible interactions with herpes viruses. Rev Med Virol, 15, pp. 179-211.
197. Giovannoni, G., Cutter, GR and Lunemann, J. (2006) Infectious causes of multiple sclerosis. Lancet Neurol, 5, pp. 887-894.
198. Alotaibi, S., Kennedy, J., Tellier, R., Stephens, D. and Banwell, B. (2004) Epstein-Barr virus in pediatric multiple sclerosis. JAMA, 291, pp. 1875-1879.
199. Pohl, D., Krone, B. and Rostasy, K. (2006) High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology, 67, pp. 2063-2065.
200. Haahr, S. and Hollsberg, P. (2006) Multiple sclerosis is linked to Epstein-Barr virus infection. Rev Med Virol, 16, pp. 297-310.
201. Nielsen, TR, Rostgaard, K. and Nielsen, NM (2007) Multiple sclerosis after infectious mononucleosis. Arch Neurol, 64, pp. 72-75.
202. DeLorenze, GN, Munger, KL, Lennette, ET, Orentreich, N., Vogelman, JH and Ascherio, A. (2006) Epstein-Barr virus and multiple sclerosis: Evidence of association from a prospective study with long-term follow-up. Arch Neurol, 63, pp. 839-844.
203. Nielsen, TR, Pedersen, M., Rostgaard, K., Frisch, M. and Hjalgrim, H. (2007) Correlations between Epstein-Barr virus antibody levels and risk factors for multiple sclerosis in healthy individuals. Mult Scler, 13, pp. 420-423.
204. Sundstrom, P., Juto, P. and Wadell, G. (2004) An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology, 62, pp. 2277-2282.
205. Bray, PF, Luka, J., Bray, PF, Culp, KW and Schlight, JP (1992) Antibodies against Epstein-Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology, 42, pp. 1798-1804.
206. Cepok, S., Zhou, D. and Srivastava, R. (2005) Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J Clin Invest, 115, pp. 1352-1360.
207. Wucherpfennig, KW and Strominger, JL (1995) Molecular mimicry in T cell-mediated autoimmunity: Viral peptides activate human T cell clones specific for myelin basic protein. Cell, 80, pp. 695-705.
208. Lang, HL, Jacobsen, H. and Ikemizu, S. (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol, 3, pp. 940-943.
209. Holmoy, T. and Vartdal, F. (2004) Cerebrospinal fluid T cells from multiple sclerosis patients recognize autologous Epstein-Barr virus-transformed B cells. J Neurovirol, 10, pp. 52-56.
210. Holmoy, T., Kvale, EO and Vartdal, F. (2004) Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol, 10, pp. 278-283.
211. Lunemann, JD, Edwards, N. and Muraro, PA (2006) Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain, 129, pp. 1493-1506.
212. Gronen, F., Ruprecht, K. and Weissbrich, B. (2006) Frequency analysis of HLA-B7-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes in patients with multiple sclerosis and healthy controls. J Neuroimmunol, 180, pp. 185-192.
213. Swanson-Mungerson, M. and Longnecker, R. (2007) Epstein-Barr virus latent membrane protein 2A and autoimmunity. Trends Immunol, 28, pp. 213-218.
214. Antony, JM, van Marle, G. and Opii, W. (2004) Human endogenous retrovirus glycoprotein-mediated induction of redox reactants causes oligodendrocyte death and demyelination. Nat Neurosci, 7, pp. 1088-1095.
215. Cooper, GS, Dooley, MA, Treadwell, EL, Clair, EW St., Parks, CG and Gilkeson, GS (1998) Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum, 41, pp. 1714-1724.
216. Hinterberger, M., Pettersson, I. and Steitz, JA (1983) Isolation of small nuclear ribonucleoproteins containing U1, U2, U4, U5, and U6 RNAs. J Biol Chem, 258, pp. 2604-2613.
217. Maddison, PJ and Reichlin, M. (1977) Quantitation of precipitating antibodies to certain soluble nuclear antigens in SLE. Arthritis Rheum, 20, pp. 819-824.
218. Bhat, NM, Bieber, MM, Yang, YC, Leu, YS, van Vollenhoven, RF and Teng, NN (2004) B cell lymphoproliferative disorders and VH4-34 gene encoded antibodies. Hum Antibodies, 13, pp. 63-68.
219. van Vollenhoven, RF, Bieber, MM and Powell, MJ (1999) VH4-34 encoded antibodies in systemic lupus erythematosus: A specific diagnostic marker that correlates with clinical disease characteristics. J Rheumatol, 26, pp. 1727-1733.
220. Heinlen, LD, McClain, MT and Merrill, J. (2007) Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthritis Rheum, 56, pp. 2344-2351.
221. Arbuckle, MR, McClain, MT and Rubertone, MV (2003) Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med, 349, pp. 1526-1533.
222. James, JA and Harley, JB (1998) B-cell epitope spreading in autoimmunity. Immunol Rev, 164, pp. 185-200.
223. Tsokos, GC, Magrath, IT and Balow, JE (1983) Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol, 131, pp. 1797-1801.
224. Harley, JB, Harley, IT, Guthridge, JM and James, JA (2006) The curiously suspicious: A role for Epstein-Barr virus in lupus. Lupus, 15, pp. 768-777.
225. Croker, JA and Kimberly, RP (2005) Genetics of susceptibility and severity in systemic lupus erythematosus. Curr Opin Rheumatol, 17, pp. 529-537.
226. Ronnblom, L., Eloranta, ML and Alm, GV (2006) The type I interferon system in systemic lupus erythematosus. Arthritis Rheum, 54, pp. 408-420.
227. Savarese, E., Chae, OW and Trowitzsch, S. (2006) U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood, 107, pp. 3229-3234.
228. Berghofer, B., Frommer, T., Haley, G., Fink, L., Bein, G. and Hackstein, H. (2006) TLR7 ligands induce higher IFN-alpha production in females. J Immunol, 177, pp. 2088-2096.
229. Parks, CG, Cooper, GS and Hudson, LL (2005) Association of Epstein-Barr virus with systemic lupus erythematosus: Effect modification by race, age, and cytotoxic T lymphocyte-associated antigen 4 genotype. Arthritis Rheum, 52, pp. 1148-1159.
230. Sarzi-Puttini, P., Atzeni, F., Iaccarino, L. and Doria, A. (2005) Environment and systemic lupus erythematosus: An overview. Autoimmunity, 38, pp. 465-472.
231. Zandman-Goddard, G. and Shoenfeld, Y. (2005) Infections and SLE. Autoimmunity, 38, pp. 473-485.
232. Kowal, C., Weinstein, A. and Diamond, B. (1999) Molecular mimicry between bacterial and self antigen in a patient with systemic lupus erythematosus. Eur J Immunol, 29, pp. 1901-1911.
233. Hemmerich, P., Neu, E., Macht, M., Peter, HH, Krawinkel, U. and von Mikecz, A. (1998) Correlation between chlamydial infection and autoimmune response: Molecular mimicry between RNA polymerase major sigma subunit from Chlamydia trachomatis and human L7. Eur J Immunol, 28, pp. 3857-3866.
234. Pyun, EH, Pisetsky, DS and Gilkeson, GS (1993) The fine specificity of monoclonal anti-DNA antibodies induced in normal mice by immunization with bacterial DNA. J Autoimmun, 6, pp. 11-26.
235. Gilkeson, GS, Pippen, AM and Pisetsky, DS (1995) Induction of cross-reactive anti-dsDNA antibodies in preautoimmune NZB/NZW mice by immunization with bacterial DNA. J Clin Invest, 95, pp. 1398-1402.
236. Shoenfeld, Y., Vilner, Y. and Coates, AR (1986) Monoclonal anti-tuberculosis antibodies react with DNA, and monoclonal anti-DNA autoantibodies react with Mycobacterium tuberculosis. Clin Exp Immunol, 66, pp. 255-261.
237. Hardgrave, KL, Neas, BR, Scofield, RH and Harley, JB (1993) Antibodies to vesicular stomatitis virus proteins in patients with systemic lupus erythematosus and in normal subjects. Arthritis Rheum, 36, pp. 962-970.
238. Rekvig, OP, Moens, U. and Sundsfjord, A. (1997) Experimental expression in mice and spontaneous expression in human SLE of polyomavirus T-antigen. A molecular basis for induction of antibodies to DNA and eukaryotic transcription factors. J Clin Invest, 99, pp. 2045-2054.
239. Perl, A., Colombo, E. and Dai, H. (1995) Antibody reactivity to the HRES-1 endogenous retroviral element identifies a subset of patients with systemic lupus erythematosus and overlap syndromes. Correlation with antinuclear antibodies and HLA class II alleles. Arthritis Rheum, 38, pp. 1660-1671.
240. Rider, JR, Ollier, WE, Lock, RJ, Brookes, ST and Pamphilon, DH (1997) Human cytomegalovirus infection and systemic lupus erythematosus. Clin Exp Rheumatol, 15, pp. 405-409.
241. Ishikawa, O., Abe, M. and Miyachi, Y. (1999) Herpes zoster in Japanese patients with systemic lupus erythematosus. Clin Exp Dermatol, 24, pp. 327-328.
242. James, JA, Harley, JB and Scofield, RH (2006) Epstein-Barr virus and systemic lupus erythematosus. Curr Opin Rheumatol, 18, pp. 462-467.
243. James, JA, Neas, BR and Moser, KL (2001) Systemic lupus erythematosus in adults is associated with previous Epstein-Barr virus exposure. Arthritis Rheum, 44, pp. 1122-1126.
244. James, JA, Kaufman, KM, Farris, AD, Taylor-Albert, E., Lehman, TJ and Harley, JB (1997) An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus. J Clin Invest, 100, pp. 3019-3026.
245. McClain, MT, Heinlen, LD, Dennis, GJ, Roebuck, J., Harley, JB and James, JA (2005) Early events in lupus humoral autoimmunity suggest initiation through molecular mimicry. Nat Med, 11, pp. 85-89.
246. James, JA, Gross, T., Scofield, RH and Harley, JB (1995) Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med, 181, pp. 453-461.
247. Arbuckle, MR, Reichlin, M., Harley, JB and James, JA (1999) Shared early autoantibody recognition events in the development of anti-Sm B/B' in human lupus. Scand J Immunol, 50, pp. 447-455.
248. James, JA and Harley, JB (1998) A model of peptide-induced lupus autoimmune B cell epitope spreading is strain specific and is not H-2 restricted in mice. J Immunol, 160, pp. 502-508.
249. Arbuckle, MR, Gross, T. and Scofield, RH (1998) Lupus humoral autoimmunity induced in a primate model by short peptide immunization. J Investig Med, 46, pp. 58-65.
250. James, JA and Harley, JB (1992) Linear epitope mapping of an Sm B/B' polypeptide. J Immunol, 148, pp. 2074-2079.
251. McClain, MT, Poole, BD, Bruner, BF, Kaufman, KM, Harley, JB and James, JA (2006) An altered immune response to Epstein-Barr nuclear antigen 1 in pediatric systemic lupus erythematosus. Arthritis Rheum, 54, pp. 360-368.
252. James, JA, Scofield, RH and Harley, JB (1997) Lupus humoral autoimmunity after short peptide immunization. Ann NY Acad Sci, 815, pp. 124-127.
253. Sundar, K., Jacques, S. and Gottlieb, P. (2004) Expression of the Epstein-Barr virus nuclear antigen-1 (EBNA-1) in the mouse can elicit the production of anti-dsDNA and anti-Sm antibodies. J Autoimmun, 23, pp. 127-140.
254. Kaufman, KM, Kirby, MY, Harley, JB and James, JA (2003) Peptide mimics of a major lupus epitope of SmB/B'. Ann NY Acad Sci, 987, pp. 215-229.
255. Incaprera, M., Rindi, L., Bazzichi, A. and Garzelli, C. (1998) Potential role of the Epstein-Barr virus in systemic lupus erythematosus autoimmunity. Clin Exp Rheumatol, 16, pp. 289-294.
256. Sabbatini, A., Bombardieri, S. and Migliorini, P. (1993) Autoantibodies from patients with systemic lupus erythematosus bind a shared sequence of SmD and Epstein-Barr virus-encoded nuclear antigen EBNA I. Eur J Immunol, 23, pp. 1146-1152.
257. Yamazaki, M., Kitamura, R. and Kusano, S. (2005) Elevated immunoglobulin G antibodies to the proline-rich amino-terminal region of Epstein-Barr virus nuclear antigen-2 in sera from patients with systemic connective tissue diseases and from a subgroup of Sjogren's syndrome patients with pulmonary involvements. Clin Exp Immunol, 139, pp. 558-568.
258. Yu, SF, Wu, HC and Tsai, WC (2005) Detecting Epstein-Barr virus DNA from peripheral blood mononuclear cells in adult patients with systemic lupus erythematosus in Taiwan. Med Microbiol Immunol, 194, pp. 115-120.
259. Moon, UY, Park, SJ and Oh, ST (2004) Patients with systemic lupus erythematosus have abnormally elevated Epstein-Barr virus load in blood. Arthritis Res Ther, 6, pp. R295-R302.
260. Kang, I., Quan, T. and Nolasco, H. (2004) Defective control of latent Epstein-Barr virus infection in systemic lupus erythematosus. J Immunol, 172, pp. 1287-1294.
261. Gross, AJ, Hochberg, D., Rand, WM and Thorley-Lawson, DA (2005) EBV and systemic lupus erythematosus: A new perspective. J Immunol, 174, pp. 6599-6607.
262. Berner, BR, Tary-Lehmann, M., Yonkers, NL, Askari, AD, Lehmann, PV and Anthony, DD (2005) Phenotypic and functional analysis of EBV-specific memory CD8 cells in SLE. Cell Immunol, 235, pp. 29-38.
263. He, B., Raab-Traub, N., Casali, P. and Cerutti, A. (2003) EBV-encoded latent membrane protein 1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J Immunol, 171, pp. 5215-5224.
264. Mackay, F. and Ambrose, C. (2003) The TNF family members BAFF and APRIL: The growing complexity. Cytokine Growth Factor Rev, 14, pp. 311-324.
265. Mackay, F., Woodcock, SA and Lawton, P. (1999) Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations. J Exp Med, 190, pp. 1697-1710.
266. Khare, SD, Sarosi, I. and Xia, XZ (2000) Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA, 97, pp. 3370-3375.
267. Groom, J., Kalled, SL and Cutler, AH (2002) Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest, 109, pp. 59-68.
268. Fletcher, CA, Sutherland, AP and Groom, JR (2006) Development of nephritis but not sialadenitis in autoimmune-prone BAFF transgenic mice lacking marginal zone B cells. Eur J Immunol, 36, pp. 2504-2514.
269. Yurasov, S., Wardemann, H. and Hammersen, J. (2005) Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med, 201, pp. 703-711.
270. Thien, M., Phan, TG and Gardam, S. (2004) Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity, 20, pp. 785-798.
271. Wakabayashi, C., Adachi, T., Wienands, J. and Tsubata, T. (2002) A distinct signaling pathway used by the IgG-containing B cell antigen receptor. Science, 298, pp. 2392-2395.
272. McClain, MT, Rapp, EC, Harley, JB and James, JA (2003) Infectious mononucleosis patients temporarily recognize a unique, cross-reactive epitope of Epstein-Barr virus nuclear antigen-1. J Med Virol, 70, pp. 253-257.
273. Costenbader, KH and Karlson, EW (2006) Epstein-Barr virus and rheumatoid arthritis: Is there a link?. Arthritis Res Ther, 8, p. 204.
274. Sawada, S., Takei, M., Inomata, H., Nozaki, T. and Shiraiwa, H. (2007) What is after cytokine-blocking therapy, a novel therapeutic target-synovial Epstein-Barr virus for rheumatoid arthritis. Autoimmun Rev, 6, pp. 126-130.
275. Oliver, JE and Silman, AJ (2006) Risk factors for the development of rheumatoid arthritis. Scand J Rheumatol, 35, pp. 169-174.
276. Stastny, P. (1978) Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med, 298, pp. 869-871.
277. Gregersen, PK, Silver, J. and Winchester, RJ (1987) The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum, 30, pp. 1205-1213.
278. Jilg, W., Bogedain, C., Mairhofer, H., Gu, SY and Wolf, H. (1994) The Epstein-Barr virus-encoded glycoprotein gp 110 (BALF 4) can serve as a target for antibody-dependent cell-mediated cytotoxicity (ADCC). Virology, 202, pp. 974-977.
279. Saal, JG, Krimmel, M. and Steidle, M. (1999) Synovial Epstein-Barr virus infection increases the risk of rheumatoid arthritis in individuals with the shared HLA-DR4 epitope. Arthritis Rheum, 42, pp. 1485-1496.
280. Padyukov, L., Silva, C., Stolt, P., Alfredsson, L. and Klareskog, L. (2004) A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis. Arthritis Rheum, 50, pp. 3085-3092.
281. Klareskog, L., Stolt, P. and Lundberg, K. (2006) A new model for an etiology of rheumatoid arthritis: Smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination. Arthritis Rheum, 54, pp. 38-46.
282. Massa, M., Mazzoli, F. and Pignatti, P. (2002) Proinflammatory responses to self HLA epitopes are triggered by molecular mimicry to Epstein-Barr virus proteins in oligoarticular juvenile idiopathic arthritis. Arthritis Rheum, 46, pp. 2721-2729.
283. Franssila, R. and Hedman, K. (2006) Infection and musculoskeletal conditions: Viral causes of arthritis. Best Pract Res Clin Rheumatol, 20, pp. 1139-1157.
284. Symmons, DP, Bankhead, CR and Harrison, BJ (1997) Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: Results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum, 40, pp. 1955-1961.
285. Bond, C. and Cleland, LG (1996) Rheumatoid arthritis: Are pets implicated in its etiology?. Semin Arthritis Rheum, 25, pp. 308-317.
286. Ray, CG, Gall, EP, Minnich, LL, Roediger, J., De Benedetti, C. and Corrigan, JJ (1982) Acute polyarthritis associated with active Epstein-Barr virus infection. JAMA, 248, pp. 2990-2993.
287. Alspaugh, MA, Jensen, FC, Rabin, H. and Tan, EM (1978) Lymphocytes transformed by Epstein-Barr virus. Induction of nuclear antigen reactive with antibody in rheumatoid arthritis. J Exp Med, 147, pp. 1018-1027.
288. Catalano, MA, Carson, DA, Slovin, SF, Richman, DD and Vaughan, JH (1979) Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis. Proc Natl Acad Sci USA, 76, pp. 5825-5828.
289. Blaschke, S., Schwarz, G., Moneke, D., Binder, L., Muller, G. and Reuss-Borst, M. (2000) Epstein-Barr virus infection in peripheral blood mononuclear cells, synovial fluid cells, and synovial membranes of patients with rheumatoid arthritis. J Rheumatol, 27, pp. 866-873.
290. Tosato, G., Steinberg, AD and Yarchoan, R. (1984) Abnormally elevated frequency of Epstein-Barr virus-infected B cells in the blood of patients with rheumatoid arthritis. J Clin Invest, 73, pp. 1789-1795.
291. Ferrell, PB, Aitcheson, CT, Pearson, GR and Tan, EM (1981) Seroepidemiological study of relationships between Epstein-Barr virus and rheumatoid arthritis. J Clin Invest, 67, pp. 681-687.
292. Balandraud, N., Meynard, JB and Auger, I. (2003) Epstein-Barr virus load in the peripheral blood of patients with rheumatoid arthritis: Accurate quantification using real-time polymerase chain reaction. Arthritis Rheum, 48, pp. 1223-1228.
293. Takeda, T., Mizugaki, Y., Matsubara, L., Imai, S., Koike, T. and Takada, K. (2000) Lytic Epstein-Barr virus infection in the synovial tissue of patients with rheumatoid arthritis. Arthritis Rheum, 43, pp. 1218-1225.
294. Takei, M., Mitamura, K. and Fujiwara, S. (1997) Detection of Epstein-Barr virus-encoded small RNA 1 and latent membrane protein 1 in synovial lining cells from rheumatoid arthritis patients. Int Immunol, 9, pp. 739-743.
295. Fox, R., Sportsman, R., Rhodes, G., Luka, J., Pearson, G. and Vaughan, J. (1986) Rheumatoid arthritis synovial membrane contains a 62,000-molecular-weight protein that shares an antigenic epitope with the Epstein-Barr virus-encoded associated nuclear antigen. J Clin Invest, 77, pp. 1539-1547.
296. Birkenfeld, P., Haratz, N., Klein, G. and Sulitzeanu, D. (1990) Cross-reactivity between the EBNA-1 p107 peptide, collagen, and keratin: Implications for the pathogenesis of rheumatoid arthritis. Clin Immunol Immunopathol, 54, pp. 14-25.
297. Kouri, T., Petersen, J. and Rhodes, G. (1990) Antibodies to synthetic peptides from Epstein-Barr nuclear antigen-1 in sera of patients with early rheumatoid arthritis and in preillness sera. J Rheumatol, 17, pp. 1442-1449.
298. Baboonian, C., Halliday, D., Venables, PJ, Pawlowski, T., Millman, G. and Maini, RN (1989) Antibodies in rheumatoid arthritis react specifically with the glycine alanine repeat sequence of Epstein-Barr nuclear antigen-1. Rheumatol Int, 9, pp. 161-166.
299. Petersen, J., Rhodes, G., Roudier, J. and Vaughan, JH (1990) Altered immune response to glycine-rich sequences of Epstein-Barr nuclear antigen-1 in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Rheum, 33, pp. 993-1000.
300. Roudier, J., Petersen, J., Rhodes, GH, Luka, J. and Carson, DA (1989) Susceptibility to rheumatoid arthritis maps to a T-cell epitope shared by the HLA-Dw4 DR beta-1 chain and the Epstein-Barr virus glycoprotein gp110. Proc Natl Acad Sci USA, 86, pp. 5104-5108.
301. Tosato, G., Steinberg, AD and Blaese, RM (1981) Defective EBV-specific suppressor T-cell function in rheumatoid arthritis. N Engl J Med, 305, pp. 1238-1243.
302. Toussirot, E., Wendling, D., Tiberghien, P., Luka, J. and Roudier, J. (2000) Decreased T cell precursor frequencies to Epstein-Barr virus glycoprotein Gp110 in peripheral blood correlate with disease activity and severity in patients with rheumatoid arthritis. Ann Rheum Dis, 59, pp. 533-538.
303. Klatt, T., Ouyang, Q. and Flad, T. (2005) Expansion of peripheral CD8+ and CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. J Rheumatol, 32, pp. 239-251.
304. David-Ameline, J., Lim, A. and Davodeau, F. (1996) Selection of T cells reactive against autologous B lymphoblastoid cells during chronic rheumatoid arthritis. J Immunol, 157, pp. 4697-4706.
305. Scotet, E., David-Ameline, J. and Peyrat, MA (1996) T cell response to Epstein-Barr virus transactivators in chronic rheumatoid arthritis. J Exp Med, 184, pp. 1791-1800.
306. Baeten, D., Peene, I. and Union, A. (2001) Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: Relevance to antifilaggrin autoantibodies. Arthritis Rheum, 44, pp. 2255-2262.
307. Pratesi, F., Tommasi, C., Anzilotti, C., Chimenti, D. and Migliorini, P. (2006) Deiminated Epstein-Barr virus nuclear antigen 1 is a target of anti-citrullinated protein antibodies in rheumatoid arthritis. Arthritis Rheum, 54, pp. 733-741.
308. Schellekens, GA, Visser, H. and de Jong, BA (2000) The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum, 43, pp. 155-163.
309. Rantapaa-Dahlqvist, S., de Jong, BA and Berglin, E. (2003) Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum, 48, pp. 2741-2749.
310. Agarwal, V., Singh, R. and Chauhan, S. (2007) Remission of rheumatoid arthritis after acute disseminated varicella-zoster infection. Clin Rheumatol, 26, pp. 779-780.
311. Pomponi, F., Cariati, R. and Zancai, P. (1996) Retinoids irreversibly inhibit in vitro growth of Epstein-Barr virus-immortalized B lymphocytes. Blood, 88, pp. 3147-3159.
312. Wolf, HJ and Morgan, AJ (1998) Epstein-Barr Virus vaccines. Herpesviruses and immunity, pp. 231-246. Plenum Press, New York
313. Gu, SY, Huang, TM and Ruan, L. (1995) First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand, 84, pp. 171-177.
314. Jones, PL and Wolffe, AP (1999) Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol, 9, pp. 339-347.
315. Robertson, KD (2001) DNA methylation, methyltransferases, and cancer. Oncogene, 20, pp. 3139-3155.
316. Robertson, KD (2002) DNA methylation and chromatin-unraveling the tangled web. Oncogene, 21, pp. 5361-5379.
317. Murray, EJ and Grosveld, F. (1987) Site specific demethylation in the promoter of human gamma-globin gene does not alleviate methylation mediated suppression. EMBO J, 6, pp. 2329-2335.
318. Kintner, C. and Sugden, B. (1981) Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells. J Virol, 38, pp. 305-316.
319. Dyson, PJ and Farrell, PJ (1985) Chromatin structure of Epstein-Barr virus. J Gen Virol, 66, pp. 1931-1940.
320. Szyf, M., Eliasson, L., Mann, V., Klein, G. and Razin, A. (1985) Cellular and viral DNA hypomethylation associated with induction of Epstein-Barr virus lytic cycle. Proc Natl Acad Sci USA, 82, pp. 8090-8094.
321. Masucci, MG, Contreras-Salazar, B. and Ragnar, E. (1989) 5-Azacytidine upregulates the expression of Epstein-Barr virus nuclear antigen 2 (EBNA-2) through EBNA-6 and latent membrane protein in the Burkitt's lymphoma line Rael. J Virol, 63, pp. 3135-3141.
322. Minarovits, J., Minarovits-Kormuta, S., Ehlin-Henriksson, B., Falk, K., Klein, G. and Ernberg, I. (1991) Host cell phenotype-dependent methylation patterns of Epstein-Barr virus DNA. J Gen Virol, 72, pp. 1591-1599.
323. Ernberg, I., Falk, K. and Minarovits, J. (1989) The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus. J Gen Virol, 70, pp. 2989-3002.
324. Minarovits, J., Hu, LF, Marcsek, Z., Minarovits-Kormuta, S., Klein, G. and Ernberg, I. (1992) RNA polymerase III-transcribed EBER 1 and 2 transcription units are expressed and hypomethylated in the major Epstein-Barr virus-carrying cell types. J Gen Virol, 73, pp. 1687-1692.
325. Hu, LF, Minarovits, J. and Cao, SL (1991) Variable expression of latent membrane protein in nasopharyngeal carcinoma can be related to methylation status of the Epstein-Barr virus BNLF-1 5'-flanking region. J Virol, 65, pp. 1558-1567.
326. Altiok, E., Minarovits, J., Hu, LF, Contreras-Brodin, B., Klein, G. and Ernberg, I. (1992) Host-cell-phenotype-dependent control of the BCR2/ BWR1 promoter complex regulates the expression of Epstein-Barr virus nuclear antigens 2-6. Proc Natl Acad Sci USA, 89, pp. 905-909.
327. Honess, RW, Gompels, UA and Barrell, BG (1989) Deviations from expected frequencies of CpG dinucleotides in herpesvirus DNAs may be diagnostic of differences in the states of their latent genomes. J Gen Virol, 70, pp. 837-855.
328. Robertson, KD and Ambinder, RF (1997) Methylation of the Epstein-Barr virus genome in normal lymphocytes. Blood, 90, pp. 4480-4484.
329. Paulson, EJ and Speck, SH (1999) Differential methylation of Epstein-Barr virus latency promoters facilitates viral persistence in healthy seropositive individuals. J Virol, 73, pp. 9959-9968.
330. Minarovits, J. (2006) Epigenotypes of latent herpesvirus genomes. Curr Top Microbiol Immunol, 310, pp. 61-80.
331. Li, H. and Minarovits, J. (2003) Host cell-dependent expression of latent Epstein-Barr virus genomes: Regulation by DNA methylation. Adv Cancer Res, 89, pp. 133-156.
332. Jones, CH, Hayward, SD and Rawlins, DR (1989) Interaction of the lymphocyte-derived Epstein-Barr virus nuclear antigen EBNA-1 with its DNA-binding sites. J Virol, 63, pp. 101-110.
333. Li, Q., Peterson, KR, Fang, X. and Stamatoyannopoulos, G. (2002) Locus control regions. Blood, 100, pp. 3077-3086.
334. Salamon, D., Takacs, M., Myohanen, S., Marcsek, Z., Berencsi, G. and Minarovits, J. (2000) De novo DNA methylation at nonrandom founder sites 5′ from an unmethylated minimal origin of DNA replication in latent Epstein-Barr virus genomes. Biol Chem, 381, pp. 95-105.
335. Robertson, KD and Ambinder, RF (1997) Mapping promoter regions that are hypersensitive to methylation-mediated inhibition of transcription: Application of the methylation cassette assay to the Epstein-Barr virus major latency promoter. J Virol, 71, pp. 6445-6454.
336. Zhou, J., Chau, CM and Deng, Z. (2005) Cell cycle regulation of chromatin at an origin of DNA replication. EMBO J, 24, pp. 1406-1417.
337. Chau, CM and Lieberman, PM (2004) Dynamic chromatin boundaries delineate a latency control region of Epstein-Barr virus. J Virol, 78, pp. 12308-12319.
338. Day, L., Chau, CM, Nebozhyn, M., Rennekamp, AJ, Showe, M. and Lieberman, PM (2007) Chromatin profiling of Epstein-Barr virus latency control region. J Virol, 81, pp. 6389-6401.
339. Kirby, H., Rickinson, A. and Bell, A. (2000) The activity of the Epstein-Barr virus BamHI W promoter in B cells is dependent on the binding of CREB/ATF factors. J Gen Virol, 81, pp. 1057-1066.
340. Tierney, RJ, Kirby, HE, Nagra, JK, Desmond, J., Bell, AI and Rickinson, AB (2000) Methylation of transcription factor binding sites in the Epstein-Barr virus latent cycle promoter Wp coincides with promoter down-regulation during virus-induced B-cell transformation. J Virol, 74, pp. 10468-10479.
341. Jansson, A., Masucci, M. and Rymo, L. (1992) Methylation of discrete sites within the enhancer region regulates the activity of the Epstein-Barr virus BamHI W promoter in Burkitt lymphoma lines. J Virol, 66, pp. 62-69.
342. Elliott, J., Goodhew, EB, Krug, LT, Shakhnovsky, N., Yoo, L. and Speck, SH (2004) Variable methylation of the Epstein-Barr virus Wp EBNA gene promoter in B-lymphoblastoid cell lines. J Virol, 78, pp. 14062-14065.
343. Hutchings, IA, Tierney, RJ, Kelly, GL, Stylianou, J., Rickinson, AB and Bell, AI (2006) Methylation status of the Epstein-Barr virus (EBV) BamHI W latent cycle promoter and promoter activity: Analysis with novel EBV-positive Burkitt and lymphoblastoid cell lines. J Virol, 80, pp. 10700-10711.
344. Takacs, M., Myohanen, S., Altiok, E. and Minarovits, J. (1998) Analysis of methylation patterns in the regulatory region of the latent Epstein-Barr virus promoter BCR2 by automated fluorescent genomic sequencing. Biol Chem, 379, pp. 417-422.
345. Evans, TJ, Jacquemin, MG and Farrell, PJ (1995) Efficient EBV superinfection of group I Burkitt's lymphoma cells distinguishes requirements for expression of the Cp viral promoter and can activate the EBV productive cycle. Virology, 206, pp. 866-877.
346. Schaefer, BC, Strominger, JL and Speck, SH (1997) Host-cell-determined methylation of specific Epstein-Barr virus promoters regulates the choice between distinct viral latency programs. Mol Cell Biol, 17, pp. 364-377.
347. Robertson, KD, Hayward, SD, Ling, PD, Samid, D. and Ambinder, RF (1995) Transcriptional activation of the Epstein-Barr virus latency C promoter after 5-azacytidine treatment: Evidence that demethylation at a single CpG site is crucial. Mol Cell Biol, 15, pp. 6150-6159.
348. Imai, S., Koizumi, S. and Sugiura, M. (1994) Gastric carcinoma: Monoclonal epithelial malignant cells expressing Epstein-Barr virus latent infection protein. Proc Natl Acad Sci USA, 91, pp. 9131-9135.
349. Robertson, KD, Manns, A., Swinnen, LJ, Zong, JC, Gulley, ML and Ambinder, RF (1996) CpG methylation of the major Epstein-Barr virus latency promoter in Burkitt's lymphoma and Hodgkin's disease. Blood, 88, pp. 3129-3136.
350. Tao, Q., Robertson, KD, Manns, A., Hildesheim, A. and Ambinder, RF (1998) Epstein-Barr virus (EBV) in endemic Burkitt's lymphoma: Molecular analysis of primary tumor tissue. Blood, 91, pp. 1373-1381.
351. Tao, Q., Swinnen, LJ, Yang, J., Srivastava, G., Robertson, KD and Ambinder, RF (1999) Methylation status of the Epstein-Barr virus major latent promoter C in iatrogenic B cell lymphoproliferative disease. Application of PCR-based analysis. Am J Pathol, 155, pp. 619-625.
352. Minarovits, J., Hu, LF, Minarovits-Kormuta, S., Klein, G. and Ernberg, I. (1994) Sequence-specific methylation inhibits the activity of the Epstein-Barr virus LMP 1 and BCR2 enhancer-promoter regions. Virology, 200, pp. 661-667.
353. Tao, Q., Robertson, KD, Manns, A., Hildesheim, A. and Ambinder, RF (1998) The Epstein-Barr virus major latent promoter Qp is constitutively active, hypomethylated, and methylation sensitive. J Virol, 72, pp. 7075-7083.
354. Schaefer, BC, Strominger, JL and Speck, SH (1995) Redefining the Epstein-Barr virus-encoded nuclear antigen EBNA-1 gene promoter and transcription initiation site in group I Burkitt lymphoma cell lines. Proc Natl Acad Sci USA, 92, pp. 10565-10569.
355. Tsai, CN, Liu, ST and Chang, YS (1995) Identification of a novel promoter located within the Bam HI Q region of the Epstein-Barr virus genome for the EBNA 1 gene. DNA Cell Biol, 14, pp. 767-776.
356. Nonkwelo, C., Skinner, J., Bell, A., Rickinson, A. and Sample, J. (1996) Transcription start sites downstream of the Epstein-Barr virus (EBV) Fp promoter in early-passage Burkitt lymphoma cells define a fourth promoter for expression of the EBV EBNA-1 protein. J Virol, 70, pp. 623-627.
357. Zetterberg, H., Stenglein, M., Jansson, A., Ricksten, A. and Rymo, L. (1999) Relative levels of EBNA1 gene transcripts from the C/W, F and Q promoters in Epstein-Barr virus-transformed lymphoid cells in latent and lytic stages of infection. J Gen Virol, 80, pp. 457-466.
358. Falk, KI, Szekely, L., Aleman, A. and Ernberg, I. (1998) Specific methylation patterns in two control regions of Epstein-Barr virus latency: The LMP-1-coding upstream regulatory region and an origin of DNA replication (oriP). J Virol, 72, pp. 2969-2974.
359. Takacs, M., Salamon, D. and Myohanen, S. (2001) Epigenetics of latent Epstein-Barr virus genomes: High resolution methylation analysis of the bidirectional promoter region of latent membrane protein 1 and 2B genes. Biol Chem, 382, pp. 699-705.
360. Salamon, D., Takacs, M., Schwarzmann, F., Wolf, H., Minarovits, J. and Niller, HH (2003) High-resolution methylation analysis and in vivo protein-DNA binding at the promoter of the viral oncogene LMP2A in B cell lines carrying latent Epstein-Barr virus genomes. Virus Genes, 27, pp. 57-66.
361. Niller, HH, Salamon, D. and Uhlig, J. (2002) Nucleoprotein structure of immediate-early promoters Zp and Rp and of oriLyt of latent Epstein-Barr virus genomes. J Virol, 76, pp. 4113-4118.
362. Bhende, PM, Seaman, WT, Delecluse, HJ and Kenney, SC (2005) BZLF1 activation of the methylated form of the BRLF1 immediate-early promoter is regulated by BZLF1 residue 186. J Virol, 79, pp. 7338-7348.
363. Bhende, PM, Seaman, WT, Delecluse, HJ and Kenney, SC (2004) The EBV lytic switch protein, Z, preferentially binds to and activates the methylated viral genome. Nat Genet, 36, pp. 1099-1104.
364. Rajcani, J. and Durmanova, V. (2000) Early expression of herpes simplex virus (HSV) proteins and reactivation of latent infection. Folia Microbiol (Praha), 45, pp. 7-28.
365. Valyi-Nagy, T., Shukla, D., Engelhard, HH, Kavouras, J. and Scanlan, P. (2007) Latency Strategies of Alphaherpesviruses. Latency strategies of herpesviruses, pp. 1-36. Springer, New York
366. Marschall, M., Alliger, P. and Schwarzmann, F. (1993) The lytic transition of Epstein-Barr virus is imitated by recombinant B cell. Arch Virol, 129, pp. 23-33.
367. Rochford, R. and Mosier, DE (1995) Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes. J Virol, 69, pp. 150-155.
368. Takada, K. and Ono, Y. (1989) Synchronous and sequential activation of latently infected Epstein-Barr virus genomes. J Virol, 63, pp. 445-449.
369. Greenspan, JS, Greenspan, D. and Lennette, ET (1985) Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion. N Engl J Med, 313, pp. 1564-1571.
370. Becker, J., Leser, U. and Marschall, M. (1991) Expression of proteins encoded by Epstein-Barr virus trans-activator genes depends on the differentiation of epithelial cells in oral hairy leukoplakia. Proc Natl Acad Sci USA, 88, pp. 8332-8336.
371. Rabanus, JP, Greenspan, D., Petersen, V., Leser, U., Wolf, H. and Greenspan, JS (1991) Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia. Am J Pathol, 139, pp. 185-197.
372. Speck, SH, Chatila, T. and Flemington, E. (1997) Reactivation of Epstein-Barr virus: Regulation and function of the BZLF1 gene. Trends Microbiol, 5, pp. 399-405.
373. Sasson, SA Ben and Klein, G. (1981) Activation of the Epstein-Barr virus genome by 5-aza-cytidine in latently infected human lymphoid lines. Int J Cancer, 28, pp. 131-135.
374. Gradoville, L., Kwa, D., Guindy, A El and Miller, G. (2002) Protein kinase C-independent activation of the Epstein-Barr virus lytic cycle. J Virol, 76, pp. 5612-5626.
375. Hsu, CH, Hergenhahn, M. and Chuang, SE (2002) Induction of Epstein-Barr virus (EBV) reactivation in Raji cells by doxorubicin and cisplatin. Anticancer Res, 22, pp. 4065-4071.
376. Kudoh, A., Fujita, M. and Zhang, L. (2005) Epstein-Barr virus lytic replication elicits ATM checkpoint signal transduction while providing an S-phase-like cellular environment. J Biol Chem, 280, pp. 8156-8163.
377. Kamel, OW, Weiss, LM, Rijn, M vende, Colby, TV, Kingma, DW and Jaffe, ES (1996) Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol, 20, pp. 1279-1287.
378. Menke, DM, Griesser, H., Moder, KG, Tefferi, A., Luthra, HS, Cohen, MD, Colon-Otero, G. and LLoyd, RV (2000) Lymphomas in patients with connective tissue disease. Comparison of p53 protein expression and latent EBV infection in patients immunosuppressed with methotrexate. Am J Clin Pathol, 113, pp. 212-218.
379. Feng, WH, Cohen, JI, Fischer, S., Li, L., Sneller, M., Goldbach-Mansky, R., Rasb-Traub, N., Delecluse, HJ and Kenney, SC (2004) Reactivation of latent Epstein-Barr virus by methotrexate: A potential contributor to methotrexate-associated lymphomas. J Natl Cancer Inst, 96, pp. 1691-1702.